Cuproptosis in Neurodegeneration

Cuproptosis in Neurodegeneration

Overview

Cuproptosis In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications. [@tsvetkov2022]

Introduction

Cuproptosis is a recently identified form of regulated cell death driven by copper-dependent proteotoxic stress. Discovered in 2022, this copper-induced cell death mechanism has emerged as a potentially important pathway in neurodegenerative diseases, where copper dyshomeostasis is frequently observed. [@wang2022]

Unlike [apoptosis](/entities/apoptosis) (which is caspase-dependent) or [ferroptosis](/entities/ferroptosis) (which is iron-dependent), cuproptosis is characterized by direct copper binding to lipoylated TCA cycle proteins, leading to proteotoxic stress and cell death. This mechanism may contribute to the neuronal loss observed in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@kaler2021]

Molecular Mechanism

Copper-Induced Proteotoxic Stress

Key Molecular Players

Cuproptosis in Neurodegeneration

Overview

Cuproptosis In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications. [@tsvetkov2022]

Introduction

Cuproptosis is a recently identified form of regulated cell death driven by copper-dependent proteotoxic stress. Discovered in 2022, this copper-induced cell death mechanism has emerged as a potentially important pathway in neurodegenerative diseases, where copper dyshomeostasis is frequently observed. [@wang2022]

Unlike [apoptosis](/entities/apoptosis) (which is caspase-dependent) or [ferroptosis](/entities/ferroptosis) (which is iron-dependent), cuproptosis is characterized by direct copper binding to lipoylated TCA cycle proteins, leading to proteotoxic stress and cell death. This mechanism may contribute to the neuronal loss observed in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@kaler2021]

Molecular Mechanism

Copper-Induced Proteotoxic Stress

Key Molecular Players

| Protein | Role in Cuproptosis |
|---------|---------------------|
| DLAT | Dihydrolipoamide S-acetyltransferase, primary copper target |
| DLST | Dihydrolipoamide S-succinyltransferase, TCA cycle enzyme |
| PDH Complex | Pyruvate dehydrogenase, lipoylated protein target |
| CTR1 (SLC31A1) | High-affinity copper transporter |
| ATP7A/ATP7B | Copper-transporting ATPases |
| MT3 | Metallothionein-3, copper buffering |
| CCS | Copper chaperone for SOD1 |
| ATOX1 | Antioxidant protein 1, copper chaperone |

Biochemical Hallmarks

Copper Homeostasis in the Brain

Normal Copper Regulation

The brain maintains strict copper homeostasis through:

• [Blood-brain barrier](/mechanisms/bbb-breakdown-ad) transport via CTR1
• Neuronal copper uptake through specific transporters
• Copper chaperones (CCS, ATOX1, COX17)
• Sequestration by metallothioneins
• ATP7A/ATP7B-mediated efflux

Copper Dysregulation in Neurodegeneration

Alzheimer's Disease:

• Elevated copper in amyloid plaques
• Copper-[Aβ](/proteins/amyloid-beta) interactions promote aggregation
• Altered copper homeostasis in AD brain
• Reduced ATP7A expression in neurons

• Increased copper in substantia nigra
• Copper-[α-synuclein](/proteins/alpha-synuclein) interactions
• Enhanced oxidative stress
• CTR1 upregulation in PD brain

• Mutations in copper metabolism genes (SOD1, ATP7A)
• Elevated brain copper in some patients
• Impaired copper handling in motor neurons
• Altered CCS expression

Therapeutic Strategies

Copper Chelation Therapy

Copper chelators represent the primary therapeutic approach for modulating cuproptosis:

| Agent | Mechanism | Clinical Status | Reference |
|-------|-----------|-----------------|-----------|
| Trientine | Selective copper chelation | Approved for Wilson's disease | [@trientine] |
| Tetrathiomolybdate (TTM) | Copper-binding protein induction | Investigational | [@tetrathiomolybdate] |
| Penicillamine | Copper chelation + excretion | Approved (Wilson disease) | [@penicillamine] |
| EDTA | Non-specific metal chelation | Limited CNS penetration | [@edta] |
| Baicalein | Natural copper chelator | Preclinical | [@baicalein] |

Copper Homeostasis Modulation

Beyond direct chelation, modulating copper transport proteins offers therapeutic potential:

• Reduce copper import
• Small molecule inhibitors in development

• Promote copper efflux from neurons
• Gene therapy approaches under investigation

• MT3 overexpression protects neurons
• Zinc supplementation may induce MT expression

Copper Ionophores and Chemical Chaperones

CuATSM (Copper(II)-diacetyl-bis(N4-methylthiosemicarbazone)):

• Delivers copper to cells in a controlled manner
• Potential for ALS treatment
• See: [CuATSM](/therapeutics/cuatsm)

Antioxidant and Proteostasis Approaches

Disease-Specific Therapeutic Approaches

Alzheimer's Disease

• Primary approach: Moderate copper chelation to reduce free copper
• Rationale: Reduce Aβ-copper interactions and oxidative stress
• Challenge: Avoid complete copper depletion (essential for cognition)
• Candidates: Trientine at low dose, natural chelators (baicalein, curcumin)

Parkinson's Disease

• Primary approach: Modulate copper-induced α-synuclein aggregation
• Rationale: Copper accelerates α-synuclein oligomerization
• Challenge: Target substantia nigra specifically
• Candidates: TTM, CuATSM for mitochondrial protection

Amyotrophic Lateral Sclerosis

• Primary approach: Restore copper homeostasis in motor neurons
• Rationale: SOD1 mutations disrupt copper handling
• Challenge: Rapid disease progression requires early intervention
• Candidates: CuATSM in clinical trials, gene therapy for ATP7A

10-Dimension Rubric Score

| Dimension | Score (1-10) | Rationale |
|-----------|-------------|-----------|
| Mechanistic Clarity | 8 | Well-defined copper-DLAT interaction pathway |
| Genetic Evidence | 7 | ATP7A/ATP7B mutations; SLC31A1 variants in PD |
| Biomarker Availability | 5 | Serum copper; limited CNS-specific markers |
| Therapeutic Targetability | 7 | Multiple druggable nodes (chelators, transporters) |
| Clinical Trial Readiness | 6 | Existing chelators can be repurposed |
| Safety Window | 5 | Copper homeostasis is delicate; narrow therapeutic window |
| Disease Relevance | 8 | Strong evidence across AD, PD, ALS |
| Combination Potential | 7 | Works with antioxidants, anti-aggregates |
| Biomarker Accessibility | 4 | Brain imaging challenging; peripheral markers incomplete |
| Regulatory Pathway | 6 | Repurposing existing chelators possible |
| TOTAL | 63/100 | |

Interpretation: Moderate-to-high priority target. The mechanistic basis is solid, but delivery to the CNS and safety monitoring remain challenges. Best suited for combination therapy approaches.

Action Plan

Phase 1: Target Validation (Year 1)

Phase 2: Therapeutic Development (Years 2-3)

Phase 3: Clinical Translation (Years 3-5)

Implementation Roadmap

Key Milestones

• Q2 2026: Validated biomarker panel
• Q4 2026: Lead compound selected
• Q2 2027: IND application submitted
• Q4 2028: Phase II readout
• Q4 2030: Potential FDA approval

Risk Mitigation

| Risk | Mitigation |
|------|------------|
| CNS penetration failure | Focus on TTM, intranasal delivery |
| Safety concerns | Start low-dose, careful monitoring |
| Patient heterogeneity | Biomarker-based stratification |
| Competition | Establish IP on novel combinations |

Cross-References

Related Mechanisms

• [Ferroptosis in Neurodegeneration](/mechanisms/ferroptosis)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
• [Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-ad)
• [Amyloid-Beta Aggregation](/mechanisms/amyloid-aggregation)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation-pathway)
• [ER Stress and Unfolded Protein Response](/mechanisms/er-stress-unfolded-protein-response)

Related Genes/Proteins

• [SLC31A1 (CTR1)](/genes/slc31a1)
• [ATP7A](/genes/atp7a)
• [ATP7B](/genes/atp7b)
• [SOD1](/genes/sod1)
• [MT3](/genes/mt3)
• [DLAT](/proteins/dlat-protein)
• [ATOX1](/genes/atox1)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Wilson's Disease](/diseases/wilsons-disease)
• [Menkes Disease](/diseases/menkes-disease)

Related Treatments

• [Metal Chelation Therapy for Neurodegeneration](/therapeutics/metal-chelation-therapy-neurodegeneration)
• [CuATSM](/therapeutics/cuatsm)

See Also

• [Copper Homeostasis in Neurodegeneration](/mechanisms/copper-homeostasis-neurodegeneration)
• [Copper Dyshomeostasis](/mechanisms/copper-dyshomeostasis)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)

Recent Research Updates (2024-2026)

• [Prophylactic self-assembled nucleic acid hydrogel targeting retinal ganglion cell cuproptosis and microglial neuroinflammation for retinal ischemia-reperfusion injury.](https://pubmed.ncbi.nlm.nih.gov/41727276/) (2026 Jun) - Bioactive materials
• [Multi-omic insight into the molecular mechanism of cuproptosis-related genes in the pathogenesis of Parkinson's disease.](https://pubmed.ncbi.nlm.nih.gov/41540060/) (2026 Jan 15) - NPJ Parkinson's disease
• [Non-Apoptotic Programmed Cell Death: From Ultrastructural Characterization to Emerging Therapeutic Opportunities.](https://pubmed.ncbi.nlm.nih.gov/41597186/) (2026 Jan 8) - Cells
• [Aging at the Crossroads of Cuproptosis and Ferroptosis: From Molecular Pathways to Age-Related Pathologies and Therapeutic Perspectives.](https://pubmed.ncbi.nlm.nih.gov/41516398/) (2026 Jan 4) - International journal of molecular sciences
• [Orchestrating pathogenesis: copper ions as the conductor of molecular dysfunction in Parkinson's disease and therapeutic avenues.](https://pubmed.ncbi.nlm.nih.gov/41772865/) (2026 Mar) - Rev Neurosci
• [Polygonatum Sibiricum polysaccharide ameliorates Alzheimer's disease by alleviating cuproptosis and activating the PI3K/AKT signaling pathway.](https://pubmed.ncbi.nlm.nih.gov/41687942/) (2026 May) - J Ethnopharmacol
• [Potential targets of microglia in the treatment of neurodegenerative diseases: Mechanism and therapeutic implications.](https://pubmed.ncbi.nlm.nih.gov/40145977/) (2026 Apr) - Neural Regen Res

References